Stockscreener 앱 받기
1.71
0.23%
0.0039
전일 마감가:
$1.7061
열려 있는:
$1.7501
하루 거래량:
2,626
Relative Volume:
0.21
시가총액:
$399.64M
수익:
$2.35M
순이익/손실:
$-2.56M
주가수익비율:
-3.8161
EPS:
-0.4481
순현금흐름:
-
1주 성능:
-10.47%
1개월 성능:
+0.00%
6개월 성능:
-5.52%
1년 성능:
-25.65%
1일 변동 폭
$1.71
$1.8158
1주일 범위
$1.50
$2.13
52주 변동 폭
$1.50
$2.87
이뮤론 Stock (IMRN) Company Profile
IMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.71 | 10.94M | 2.35M | -2.56M | 0 | -0.4481 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
이뮤론 주식(IMRN)의 최신 뉴스
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - Markets Insider
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron Travelan® continued strong sales growth - GlobeNewswire Inc.
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
Immuron Travelan® continued strong sales growth - The Manila Times
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - GlobeNewswire
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive Investors Australia
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - GlobeNewswire
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com UK
Immuron Limited Announces Participation in the LD Micro Invitational XIII - The Kingston Whig-Standard
Immuron US DoD Naval Medical Research Center responds to - GlobeNewswire
Immuron Surges On U.S. DoD Funding For Travelan Research By Investing.com - Investing.com Nigeria
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic - StockTitan
Immuron LimitedADR Shares Close the Week 61.5% HigherWeekly Wrap - Nasdaq
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak - GlobeNewswire
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33% - Investing.com
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
IMC Stock Price and Chart — ASX:IMC - TradingView
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):